The BA.3.2 variant, commonly referred to as the Cicada variant, was first identified in South Africa in November 2024. This variant is a descendent of BA.3, an omicron subvariant that emerged in 2022. With approximately 70 to 75 mutations in its spike protein, the Cicada variant has raised concerns among health experts regarding its transmissibility and potential impact on public health.

Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. Most cases of the Cicada variant appear mild to moderate, resembling flu-like illness, especially among vaccinated individuals. Health experts have noted that symptoms linked to the Cicada variant remain largely consistent with previous COVID-19 strains.

Current evidence suggests that the BA.3.2 variant does not cause more severe illness compared to earlier variants. Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” This reassurance is echoed by health authorities who emphasize that most cases can be managed at home with rest and hydration.

Despite the presence of multiple mutations, vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. However, some experts warn that the current COVID-19 vaccines may not be as effective against the Cicada variant due to its numerous mutations. Observers are closely monitoring the situation as the variant has been detected in over 20 countries and is currently on the rise in the United States, with reports of cases in at least 25 states.

Health authorities recommend that individuals stay up to date with vaccinations and take precautions in crowded settings to mitigate the spread of the Cicada variant. The variant primarily spreads through respiratory droplets and close contact in crowded or poorly ventilated spaces, which underscores the importance of public health measures.

As the situation evolves, health experts continue to analyze the implications of the Cicada variant. They emphasize that symptoms of the BA.3.2 Cicada variant are largely similar to earlier Omicron strains, with no new or unusual signs reported so far. However, details remain unconfirmed regarding the long-term effects of this variant and its potential to evade immune responses.

In summary, while the emergence of the Cicada variant has prompted increased vigilance among health authorities, the current understanding suggests that it does not significantly alter the landscape of COVID-19 severity. Continued monitoring and adherence to health guidelines remain crucial as the situation develops.

The post Cicada COVID Variant Symptoms: What You Need to Know appeared first on newsrush.

The emergence of the Cicada COVID-19 variant has raised significant concern globally, particularly as it has now been detected in India. This variant, classified as BA.3.2, is an offshoot of the Omicron family tree, indicating it is not a completely new threat but rather a continuation of the ongoing battle against COVID-19.

First spotted in South Africa in November 2024, the Cicada variant carries around 75 mutations, with over 50 of these located in the spike protein. This extensive mutation profile has led to increased scrutiny from health authorities worldwide.

Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash. While these symptoms are concerning, it is important to note that the Cicada variant is not confirmed to cause more severe illness than previous variants.

As of now, the variant has been detected in 22 countries, including India, which has prompted health officials to monitor its spread closely. The first confirmed case of the Cicada variant in the United States was reported in June 2025, and by January 2026, three patients had been confirmed, all of whom recovered.

Dr. Robert Hopkins Jr. has stated, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This highlights the uncertainty surrounding the variant’s potential impact on public health.

The Centers for Disease Control and Prevention (CDC) emphasized the importance of monitoring the spread of BA.3.2, noting that it provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations.

Details remain unconfirmed regarding the real-world data on the severity of illness caused by the Cicada variant. As health authorities continue to gather information, the situation remains fluid.

In conclusion, the detection of the Cicada variant in India underscores the ongoing challenges posed by COVID-19 and the need for vigilance in monitoring and responding to new variants as they emerge.

The post Cicada COVID Variant in India: Latest Developments appeared first on newsrush.